Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB221 vs Trastuzumab in HER2-positive Breast Cancer
NCT04170595Phase 2Unknown
- Sponsor
- Genor Biopharma
- Start
- Mar 2014
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of coprelotamab in breast cancer, sponsored by Genor Biopharma. Status: unknown.
02
Drugs
coprelotamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04170595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170595.